Home Compare DD vs PFE
Stock Comparison · Valuation-led comparison

DuPont de Nemours vs Pfizer: Which Stock Looks Stronger in 2026?

The structural profiles are close, with Pfizer carrying a narrow edge on valuation. DuPont de Nemours still has the edge on profitability, which keeps the comparison from looking entirely one-sided. The market setup is broadly comparable for both — no clear directional signal from price behavior. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

The comparison is mainly decided in valuation, with the rest of the profile carrying less weight.

Trajectory Similarity
0.58
Moderately similar
Peer-set rank: #11
within DuPont de Nemours, Inc.'s functional peer set

These two companies are linked by measured long-term financial trajectory similarity within the selected peer universe.

The pair shares a valid long-term profile match, but the trajectories are not especially close.

Most of the shared profile comes through margin trend and recent revenue growth.

Similarity drivers
margin trendrecent revenue growth
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
DD
DuPont de Nemours, Inc.
38
Peer-Score
Signal qualityHigh
vs
PFE
Pfizer Inc.
42
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

Pricing shapes this comparison more than a broad operating gap.

Dimension spread: DD vs PFE Profitability 65 12 Stability 42 48 Valuation 8 82 Growth 19 DD PFE
Gap Ranking
#1 Valuation +74
#2 Profitability +53
#3 Stability +6
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for DD and PFE Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer DDPFE Relative valuation Structural strength

DuPont de Nemours, Inc. still looks stronger overall, though current pricing looks more supportive for Pfizer Inc..

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Valuation
On valuation, Pfizer Inc. ranks near the top of the group; DuPont de Nemours, Inc. sits in the weaker half.
Profitability
On profitability, the gap still runs the same way: DuPont de Nemours, Inc. sits near the top of the group, while Pfizer Inc. remains in the weaker half.
Valuation — Dominant Gap
DD
8
PFE
82
Gap+74in favour of PFE

The multiple-based pricing edge comes from a forward P/E that is 8.2 turns lower.

What keeps the gap from being one-sided

Profitability still favours DuPont de Nemours, with a 10.7-point operating margin advantage keeping the comparison from looking fully resolved.

What this means for the comparison

Valuation is the clearest driver of the lead, with profitability adding further support — though profitability still provides a real counterweight.

Explore full peer positioning in AssetNext

Break down the DD vs PFE comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Other comparisons with conflicting dimension signals

Explore how DD and PFE each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.